RNS Number : 9778S
LiDCO Group Plc
28 May 2009
 




Press Release 

28 May 2009

                        

LiDCO Group Plc

("LiDCO" or the "Company")

Grant of Share Options


The Board of LiDCO Group Plc (AIM: LID), the cardiovascular monitoring company, announces that on 27 May 2009, in accordance with the Company's Employee Share Option Schemes, the following options were granted to subscribe for new ordinary shares in the Company to three Directors and to the Company Secretary as follows:


Director

Number

Exercise Price

Exercise Period

Total Number of options held


Terry O'Brien

150,000

12.67p

2012 - 2019

1,177,395

John Barry

150,000

12.67p

2012 - 2019

3,237,017

Paul Clifford

  75,000

12.67p

2012 - 2019

  141,000


Company Secretary





John Rowland

  25,000

12.67p

2012 - 2019

  90,000

 


In addition, options over a further 809,000 new ordinary shares have been granted to employees of the Company on the same terms.


- ENDS -

For more information please contact:

LiDCO Group Plc


Terry O'Brien - Chief Executive

John Rowland - Company Secretary

Tel: +44 (0)20 7749 1500

www.lidco.com


FinnCap


Geoff Nash / Marc Young / Stephen Norcross

+44 (0)20 7600 1658

www.finncap.com 



Media enquiries


Abchurch Communications


Heather Salmond / Stephanie Cuthbert / Simone Alves 

+44 (0)20 7398 7728

www.abchurch-group.com





About LiDCO Group Plc


LiDCO is a leading supplier of minimally invasive hemodynamic monitoring equipment and disposables. These are used primarily for the management of hospital patients requiring critical care or at major cardiovascular risk. LiDCO's computer-based technology significantly reduces the complications (particularly infections) and costs associated with major surgery. The technology was invented in the Department of Applied Physiology based at St Thomas' Hospital, London. LiDCO is based in the UK and its shares are traded on AIM. For more information please see www.lidco.com.


The Company's manufacturing facility is in Hoxton, London, and its current products are:

* LiDCOplus is a computer-based platform monitor used in the Intensive Care Unit for real-time continuous display of hemodynamic parameters including cardiac output, oxygen delivery and fluid-volume responsiveness (PPV% and SVV%)


* LiDCOrapid: our new cardiac output monitor designed specifically for use in the Operating Theatre for fluid and drug management at the point of care. The monitor features many clinical benefits. These enable acute-care physicians to get accurate and immediate feedback on the patient's fluid and hemodynamic status - a key measure of overall well-being during and after surgery. 

* Early and rapid warning of change

* Clear indication of therapeutic route: fluid or drug

* Quantification of hemodynamic response, particularly stroke volume

* Permits more effective delivery of fluids - the right amount at the right time

*Advanced hemodynamic care has been shown to:

- Contribute to reduced morbidity and complications

- Reduce length of stay

- Reduce overall cost of care


* LiDCO single-patient-use disposables used in conjunction with the LiDCOplus and LiDCOrapid Monitors. 


* LiDCOview: an easy-to-use graphical display of historical LiDCOplus hemodynamic data. Both clinical researchers and routine users can view beat-to-beat hemodynamic data collected with the LiDCOplus. LiDCOviewSE is the standard version of this tool and is available for free, allowing anyone to download and access data from the LiDCOplus. LiDCOviewPRO is the Professional version, allowing users to analyse, export and report the LiDCOplus data. A free trial of LiDCOviewPRO is available for evaluation purposes prior to purchase


LiDCO Distribution Network:

The Company sells direct to hospitals in the UK, and elsewhere predominantly through a worldwide network of specialty critical care and anesthesia distributors.

 



This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSMGGZKKRZGLZM